·PIB·15 marks·250–350 words

India's participation in intergovernmental science bodies such as ICGEB is an instrument of science diplomacy for the Global South. Discuss.

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. ICGEB as an instrument of India's science diplomacy
  2. Limitations
  3. Way forward

Science diplomacy means using scientific cooperation to build ties between nations. The International Centre for Genetic Engineering and Biotechnology (ICGEB) is an intergovernmental body with components in Trieste, New Delhi and Cape Town [1]. It gives India a platform to act as a knowledge partner for the Global South, although the results so far are more promise than proof.

ICGEB as an instrument of India's science diplomacy

  • Institutional weight: India hosts one of only three components. The Department of Biotechnology (DBT) supports the New Delhi campus [1][2].
  • Capacity building: ICGEB New Delhi trained 67 researchers from 22 countries in 2023–26 [1]. This builds lasting networks with Asia and Africa, which is soft power.
  • Technology transfer: ICGEB's mandate covers training and transfer of know-how to developing and emerging economies [1].
  • Solutions to shared problems: its work on climate-resilient crops, carbon capture, bio-ethanol, vaccines and monoclonal antibodies [1] matches Global South priorities in food, health and energy.
  • Showcasing India's model: the research is aligned with the BioE3 Policy (Cabinet-approved, Aug 2024) [3]. India's first biofoundry for microbial biomanufacturing is at ICGEB India [1].
  • Shared facilities: the minister's November 2026 visit to Trieste showcased a new BSL-3 lab, a high-throughput screening facility and biopharma training facilities [1]. Member countries can use these without each building their own.

Limitations

  • Small scale: about 20 trainees a year, or roughly 3 per country, is too few to claim leadership of the Global South.
  • Asymmetry: the newest high-containment lab is in Italy, not India [1].
  • Opaque returns: there is no public data on India's payments to ICGEB, patents filed or technologies licensed.
  • Biosafety and dual-use risks: BSL-3 and genome-editing research need strict access rules and open regulation.

Way forward

  • DBT should publish a yearly ICGEB report card covering payments, joint papers, patents and where trainees went next.
  • Expand fellowships for African and Asian researchers.
  • Seek a BSL-3 facility at New Delhi, with dual-use safeguards.
  • Connect the biofoundry to the BioE3 manufacturing hubs.

Overall, ICGEB is a real but still young tool of India's science diplomacy. If it grows in scale and becomes transparent, it can advance SDG 17 (Partnerships for the Goals) and the spirit of Vasudhaiva Kutumbakam. That would make India a trusted, long-term science partner for the Global South.

Sources

  1. 1Press Information Bureau: Dr. Jitendra Singh visits ICGEB Trieste (Nov 2026)ICGEB's nature, mandate and three components; DBT support; 67 researchers from 22 countries; BSL-3, screening and biopharma facilities; research areas; first microbial-biomanufacturing biofoundry; BioE3 alignment
  2. 2Department of Biotechnology: International Centre for Genetic Engineering and BiotechnologyNew Delhi component listed among DBT's international bodies
  3. 3PIB: Cabinet approves BioE3 Policy for fostering high-performance biomanufacturing (Aug 2024)BioE3 approval and objective

More from this note